SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Eli Lilly -- Ignore unavailable to you. Want to Upgrade?


To: John Carragher who wrote (422)11/19/1998 8:26:00 PM
From: Anthony Wong  Read Replies (1) | Respond to of 642
 
From labpuppy.com - October prescription trends for some of the major drug
categories:

Allergy drugs - +18% (Schering-Plough's Claritin, Pfizer's Zyrtec and Hoechst's
Allegra
showed good growth)
Antibiotics - +28% (led by Pfizer's Zithromax)
Antipsychotics - +21% (lead by Eli Lilly's Zyprexa and Johnson & Johnson's
Risperdal)
Asthma anti-inflammatories - +24% (lead by strong growth from Merck's Singular)
Cholesterol drugs - +19% (lead by strong growth from Warner-Lambert's Lipitor)
Depression drugs - +12% (Eli Lilly's Prozac new prescription growth was only 1%)
Oral diabetes drugs - +10% (Warner-Lambert's Rezulin new prescriptions fell by 9%)
Osteoporosis drugs - +63% (Eli Lilly's Evista is gaining share from Merck's Fosamax)

labpuppy.com